订阅最新相关文献

A method for stratifying an individual with vulvodynia or genetically predisposed to one or more phenotypic traits associated with vulvodynia.

There is described a set of oligonucleotides for determining the presence or absence of at least two enteric pathogens, said set of oligonucleotides comprising (a) and at least one of (b)-(e): (a) a Shigatoxigenic E. coli (STEC)-specific amplification oligomer set omprising first and second oligomers respectively comprising target-hybridizing sequences consisting of the nucleotide sequences of: (i) SEQ ID NO:20 and SEQ ID NO:3; (ii) SEQ ID NO:49 and SEQ ID NO:3; or (iii) SEQ ID NON and SEQ ID NO:7; (b) a Salmonella-specific amplification oligomer set comprising first and second oligomers respectively comprising target-hybridizing sequences consisting of the nucleotide sequences of: (i) SEQ ID NO:12 and SEQ ID NO:14; (ii) SEQ ID NO:21 and SEQ ID NO:47; (iii) SEQ ID NO:38 and SEQ ID NO:36; (iv) SEQ ID NO:35 and SEQ ID NO:40; (v) SEQ ID NO:12 and SEQ ID NO:28; (vi) SEQ ID NO:42 and SEQ ID NO:31; or (vii) SEQ ID NO:41 and SEQ ID NO:27; (c)a C. jejuni-specific amplification oligomer set comprising first and second oligomers respectively comprising target-hybridizing sequences consisting of the nucleotide sequences of: SEQ ID NO:11 and SEQ ID NO:19; (d) a C. coli-specific amplification oligomer set comprising first and second oligomers respectively comprising target-hybridizing sequences consisting of the nucleotide sequences of: (i) SEQ ID NO:8 and SEQ ID NO:10; and (e) a Shigella-specific amplification oligomer set comprising first and second oligomers respectively comprising target-hybridizing sequences consisting of the nucleotide sequences of: (i) SEQ ID NO:15 and SEQ ID NO:17; (ii) SEQ ID NO:34 and SEQ ID NO:22; or (iii) SEQ ID NO:32 and SEQ ID NO:33.

The disclosure features non-invasive methods for diagnosing non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), and liver fibrosis in a subject by, e.g., determining the level of one or more lipids, glycans, hormones, and/or fatty acids in a biological sample (e.g., a blood, serum, or plasma sample) obtained from the subject. Also described are methods of treating, monitoring, or evaluating the efficacy of a treatment for NAFL, NASH, or liver fibrosis in a subject based on the level of one or more lipids, glycans, hormones, and/or fatty acids in a biological sample (e.g., a blood, serum, or plasma sample) obtained from the subject.

This invention describes a method for extracting genomic DNA from nasopharyngeal swabs of individuals infected with SARS-CoV-2 (and other pathogens) using chelex®100 resin. The protocol details the treatment of nasopharyngeal swab samples with chelex®100, resulting in high-quality DNA for genetic analysis. Compared to traditional and commercial methods, the chelex®100 method offers lower cost, fewer steps, moderate execution time, higher final volume, higher DNA concentration and yield, and lower purity. DNA integrity is maintained in agarose gel, and amplification by PCR-RFLP and qRT-PCR is effective. The results indicate that the chelex®100 method is a viable and efficient alternative for DNA extraction, meeting the cost, time, and quality requirements for genetic studies related to COVID-19 and other diseases.

FIELD: molecular biology, laboratory diagnostics, genetics.SUBSTANCE: method for determining the CCR5del32 polymorphism in the gene encoding the human chemokine receptor CCR5 is proposed. Accelerated express DNA extraction is carried out from cell lines and buccal epithelium; to amplify a fragment of the CCR5 gene containing a deletion region encoding the chemokine receptor CCR5 in the human genome, a combination of primers SEQ ID NO 1 and SEQ ID NO 2 is used. The PCR reaction mixture is prepared based on a reagent kit containing highly processive recombinant HS-Taq DNA polymerase and the intercalating fluorescent dye SYBR Green I. Next, the amplification reaction is set up immediately after amplification in the same amplification protocol, a high-resolution HRM melting curve analysis with reading via the SYBR Green I channel follows. The results are determined using an analysis of the high-resolution melting curve derivative graph: the wild-type homozygote WT/WT is characterized by one peak with a maximum at 76.5 °C, for the homozygote of the mutant type MT/MT, one peak with a maximum at 74 °C is characteristic, for the WT/MT heterozygote, two peaks are characteristic with maxima at 74 °C and 76.5 °C. As a result, the CCR5del32 genotype is determined.EFFECT: method allows to determine the CCR5del32 genotype.1 cl, 1 dwg, 1 tbl, 1 ex

To more effectively amplify a target nucleic acid.SOLUTION: The primer set is represented by SEQ ID NO: 1 and SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 10, or SEQ ID NO: 9 and SEQ ID NO: 12.SELECTED DRAWING: Figure 6

The present invention relates to biomarkers for the diagnosis of colorectal cancer and the prediction of prognosis after colorectal cancer surgery, and the use thereof. The five blood-derived exosome miRNAs (miR-365a-5p, miR-181a-5p, miR-616-3p, miR-640, and miR-1251-3p) according to the present invention can be measured simply by blood collection, which offers excellent accessibility for patients in colorectal cancer diagnostic testing. Furthermore, since the diagnosis targets exosome miRNAs—that is, miRNAs contained within extracellular vesicles—as blood biomarkers, there is an advantage in that relatively stable and accurate diagnosis is possible. Accordingly, the blood-derived exosome miRNAs according to the present invention are expected to be usefully utilized as biomarkers for the diagnosis of colorectal cancer and the prediction of prognosis after colorectal cancer surgery.

IMPROVED DETECTION OF SHORT HOMOPOLYMERIC REPEATS. This application relates to the detection of nucleotide number changes in short homopolymeric nucleic acid repeats, in particular in short homopolymeric microsatellites, for example, for the purpose of diagnosing microsatellite instability (MSI) and/or mismatch repair (MMR) deficiency in tumors. Consequently, methods are provided for detecting nucleotide number changes present in sequences of short homopolymeric nucleotide repeats, as well as kits and cartridges for the automated detection of said changes.

The invention relates to the field of secondary markers for microRNA activity, and in particular the invention relates to the identification of Serpine1 as a mRNA which is repressed by microRNA-134 in neuronal cells, and the use of Serpine1 mRNA or protein as a biomarker for microRNA-134 modulation, such as a biomarker for antisense oligonucleotide inhibitors of microRNA-134.